Form D · Biotechnology
GENIE Therapeutics, Inc.
Wilmington, DE · CIK 0001987607
Offering snapshot reported Nov 17, 2023 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors1 → 0
- Minimum accepted$0 → $5,000
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 17, 2023 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Jul 27, 2023 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-488093
Sales made prior to the date of the filing of this Form D/A were made pursuant to 506(b), and sales made subsequent to the filing of this Form D/A will be made pursuant to 506(c).
Source: Form D, filed Nov 17, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aaron Tabor | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1207 Delaware Avenue #1118
Wilmington, DE, 19806
Wilmington, DE, 19806